AGNP.F Stock Overview
Operates as a clinical stage pharmaceutical development company in Canada and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Algernon Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.062 |
| 52 Week High | CA$0.12 |
| 52 Week Low | CA$0.037 |
| Beta | 1.83 |
| 1 Month Change | 19.81% |
| 3 Month Change | 7.23% |
| 1 Year Change | -46.42% |
| 3 Year Change | -94.00% |
| 5 Year Change | -98.96% |
| Change since IPO | -99.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| AGNP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.8% | -1.3% | -0.3% |
| 1Y | -46.4% | -9.7% | 11.3% |
Return vs Industry: AGNP.F underperformed the US Pharmaceuticals industry which returned -11.5% over the past year.
Return vs Market: AGNP.F underperformed the US Market which returned 9.1% over the past year.
Price Volatility
| AGNP.F volatility | |
|---|---|
| AGNP.F Average Weekly Movement | 25.8% |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: AGNP.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AGNP.F's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Chris Moreau | algernonpharmaceuticals.com |
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries.
Algernon Pharmaceuticals Inc. Fundamentals Summary
| AGNP.F fundamental statistics | |
|---|---|
| Market cap | US$1.68m |
| Earnings (TTM) | US$194.71k |
| Revenue (TTM) | n/a |
Is AGNP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGNP.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | -CA$269.14k |
| Earnings | CA$269.14k |
Last Reported Earnings
Feb 28, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0099 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AGNP.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 13:21 |
| End of Day Share Price | 2025/05/27 00:00 |
| Earnings | 2025/02/28 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Algernon Pharmaceuticals Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andre Uddin | Research Capital Corporation |